Krystal Biotech Statistics

Total Valuation

Krystal Biotech has a market cap or net worth of EUR 3.50 billion. The enterprise value is 2.85 billion.

Market Cap	3.50B
Enterprise Value	2.85B

Important Dates

The next estimated earnings date is Monday, August 4, 2025.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	28.90M
Shares Outstanding	n/a
Shares Change (YoY)	+4.32%
Shares Change (QoQ)	-0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	22.81M

Valuation Ratios

The trailing PE ratio is 30.55 and the forward PE ratio is 18.76.

PE Ratio	30.55
Forward PE	18.76
PS Ratio	11.36
PB Ratio	3.85
P/TBV Ratio	3.85
P/FCF Ratio	29.28
P/OCF Ratio	27.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.04, with an EV/FCF ratio of 23.83.

EV / Earnings	24.86
EV / Sales	9.90
EV / EBITDA	24.04
EV / EBIT	24.71
EV / FCF	23.83

Financial Position

The company has a current ratio of 9.65, with a Debt / Equity ratio of 0.01.

Current Ratio	9.65
Quick Ratio	9.06
Debt / Equity	0.01
Debt / EBITDA	0.07
Debt / FCF	0.07
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 13.90% and return on invested capital (ROIC) is 9.27%.

Return on Equity (ROE)	13.90%
Return on Assets (ROA)	8.66%
Return on Invested Capital (ROIC)	9.27%
Return on Capital Employed (ROCE)	13.42%
Revenue Per Employee	1.12M
Profits Per Employee	417,047
Employee Count	275
Asset Turnover	0.35
Inventory Turnover	1.11

Taxes

In the past 12 months, Krystal Biotech has paid 13.01 million in taxes.

Income Tax	13.01M
Effective Tax Rate	10.19%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	44.34
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.49

Income Statement

In the last 12 months, Krystal Biotech had revenue of EUR 308.51 million and earned 114.69 million in profits. Earnings per share was 3.84.

Revenue	308.51M
Gross Profit	287.53M
Operating Income	123.57M
Pretax Income	127.70M
Net Income	114.69M
EBITDA	125.74M
EBIT	123.57M
Earnings Per Share (EPS)	3.84

Full Income Statement

Balance Sheet

The company has 570.71 million in cash and 8.94 million in debt, giving a net cash position of 699.13 million.

Cash & Cash Equivalents	570.71M
Total Debt	8.94M
Net Cash	699.13M
Net Cash Per Share	n/a
Equity (Book Value)	911.02M
Book Value Per Share	31.52
Working Capital	635.90M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 128.14 million and capital expenditures -8.50 million, giving a free cash flow of 119.65 million.

Operating Cash Flow	128.14M
Capital Expenditures	-8.50M
Free Cash Flow	119.65M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 93.20%, with operating and profit margins of 40.05% and 37.18%.

Gross Margin	93.20%
Operating Margin	40.05%
Pretax Margin	41.39%
Profit Margin	37.18%
EBITDA Margin	40.76%
EBIT Margin	40.05%
FCF Margin	38.78%

Dividends & Yields

Krystal Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.32%
Shareholder Yield	n/a
Earnings Yield	3.27%
FCF Yield	3.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Krystal Biotech has an Altman Z-Score of 35.19 and a Piotroski F-Score of 5.

Altman Z-Score	35.19
Piotroski F-Score	5